CEO of Everest Medicines, Rogers Yongqing Luo, is confident that the appointments of Ms. Zeng and Mr. Liang will expedite the company's strategic growth. They are anticipated to spearhead their teams and foster strategic integration, promoting successful commercialization of Everest's products and long-term value creation.
$Hang Seng Index(800000.HK)$plunge deepened unceasingly after midday. It once stumbled 620 pts or 3.9% to bottom at 15,245, hitting an over-14-month low; last at 15,320, down 545 pts or 3.4%, with a total turnover of $88.5 billion. Pharmaceuticals were sold off.$REMEGEN-B(09995.HK)$once collapsed 27.5% to $22.8; last at $24.9, down 21%. $CLOVER BIO-B(02197.HK)$nosedived 9.6% to $0.47, hitting record low.$維亜生物科技(01873.HK)$...
$EVEREST MED-B(01952.HK)$On September 13, Genting Sunshine announced that it would introduce Providence's mRNA COVID-19 vaccine at a total price of 2.583 billion yuan, and the two parties will also cooperate in the development of two mRNA vaccines in the future.
1
1
報告
102252270 :
ia there any positive update about everest?
EVEREST MED-Bに関するコメント
HSI Plunge Once Deepens to 620 Pts; Pharmas In Sell-off
Pharmaceuticals were sold off. $REMEGEN-B(09995.HK)$ once collapsed 27.5% to $22.8; last at $24.9, down 21%.
$CLOVER BIO-B(02197.HK)$ nosedived 9.6% to $0.47, hitting record low. $維亜生物科技(01873.HK)$ ...
まだコメントはありません